Pluri, Inc.

As of May 13, 2025, Pluri, Inc. is considered a risky investment due to its negative financial metrics, including a Price to Book Value of -8.32 and an EV to EBITDA ratio of -1.69, alongside poor stock performance with a 1-year return of -13.35% compared to the S&P 500's 17.14%.

As of May 13, 2025, Pluri, Inc. is rated as "risky" and overvalued, with negative financial ratios and a 5-year return of -93.18%, significantly underperforming compared to its peers and the S&P 500.

As of May 19, 2025, Pluri, Inc. is in a mildly bearish trend, indicated by bearish momentum from the weekly MACD and daily moving averages, despite some mildly bullish signals from the monthly MACD and Dow Theory.

As of March 2022, the management team of Pluri, Inc. includes Zalman Aberman (Executive Chairman), Yaky Yanay (CEO), Doron Shorrer (Lead Independent Director), Rami Levy, Maital Shemesh-Rasmussen, Isaac Braun, and Mark Germain (Independent Directors). They oversee the company's strategic direction and governance.

Pluri, Inc. develops placenta-based cell therapy products for ischemic, inflammatory, and hematologic conditions, operating as a micro-cap company with a market cap of $33.21 million. As of March 2025, it reported net sales of $0 million and a net loss of $6 million.

As of Jun 18, Pluri, Inc. has a market capitalization of 33.21 million, with net sales of 1.04 million and a net profit of -21.34 million over the last four quarters. As of Jun 24, the company reported shareholder's funds of 0.10 million and total assets of 39.53 million.